Prognostic and clinical implication of a disintegrin and metalloprotease 8 expression in pediatric medulloblastoma

Abstract

AimTo investigate the expression patterns and clinical value of a disintegrin and metalloprotease 8 (ADAM8) in pediatric medulloblastoma. MethodsWe evaluated the expression of ADAM8 mRNA and protein in pediatric medulloblastoma tissues by Quantitative RT-PCR, Western blot analysis and Immunohistochemical staining, respectively. The correlation of ADAM8 immunostaining with clinical-pathological features of medulloblastoma patients and its prognostic relevance were further determined. ResultsADAM8 mRNA and protein were both most highly expressed in medulloblastoma tissues when compared with normal cerebellum tissues (both P<0.001). According to the immunohistochemisty analysis, we found statistically significant correlations of high ADAM8 protein expression with advanced metastatic stage (P=0.01), aggressive histopathological type (P=0.006), as well as with undifferentiated tumor (P=0.02). We further determined a statistically significant association between ADAM8 protein expression and clinical outcome of medulloblastoma patients, with higher expression levels of ADAM8 associating with a worse overall survival (P=0.02). ConclusionOur results provide the first evidence that the up-regulation of ADAM8 in medulloblastoma tissues might be correlated with the advanced tumor progression and poor prognosis of patients with this disease. Detection of ADAM8 expression might facilitate the prognostic assessment and improve the therapeutic strategy for medulloblastoma patients.